Advantage Alpha Capital Partners LP Entrada Therapeutics, Inc. Put Options Transaction History
Advantage Alpha Capital Partners LP
- $515 Million
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding TRDA
# of Institutions
76Shares Held
25.7MCall Options Held
0Put Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$68.8 Million0.87% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$62.5 Million25.58% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$62.3 Million22.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.75MShares$38.9 Million0.0% of portfolio
-
Black Rock Inc. New York, NY1.49MShares$21 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $443M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...